In this large series, the investigators evaluated the short-and long-term safety of infliximab in
patients with Crohn's disease. Using pharmacy records, 500 patients with Crohn's disease …

In this large series, the investigators evaluated the short-and long-term safety of infliximab in
patients with Crohn's disease. Using pharmacy records, 500 patients with Crohn's disease …

Background & Aims: The aim of this study was to evaluate the short-and long-term safety of
infliximab in patients with Crohn's disease in clinical practice. Methods: The medical records …

The study by Lichtenstein et al. analyzed the long-term safety of infliximab in patients with
Crohn's disease using data of the large Crohn's Therapy, Resource, Evaluation, and …

Infliximab is a monoclonal chimeric antibody, with high affinity and specificity for tumour
necrosis factor alpha (TNFalpha) that plays a central role in the pathogenesis of immune …

Infliximab is a chimeric monoclonal antibody against anti-tumour necrosis factor alpha that
has changed the management of inflammatory bowel diseases. Our review describes its …

OBJECTIVE: To determine whether the clinical efficacy and safety of infliximab in diverse
clinical referral practices was similar to that seen in the randomized, controlled clinical trials …

Background The aim of this study was to evaluate the short-and long-term safety experience
of infliximab treatment in patients with Crohn's disease (CD) in clinical practice. Methods The …

Infliximab is a chimeric anti-tumour necrosis factor-alpha monoclonal antibody that has been
studied for the treatment of Crohn's disease and rheumatoid arthritis. In several placebo …

In the evaluation of a new treatment, particularly for a novel agent such as infliximab, there is
a critical requirement to evaluate efficacy and the adverse event profile. Although a clinical …